

Benjamin Ruf

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3593295/publications.pdf>

Version: 2024-02-01

19
papers

647
citations

840119

11
h-index

1058022

14
g-index

19
all docs

19
docs citations

19
times ranked

723
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells. Cellular and Molecular Immunology, 2021, 18, 112-127.	4.8	159
2	Gut Microbiome Directs Hepatocytes to Recruit MDSCs and Promote Cholangiocarcinoma. Cancer Discovery, 2021, 11, 1248-1267.	7.7	117
3	CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma. Journal of Hepatology, 2021, 74, 1145-1154.	1.8	76
4	The tumour microenvironment shapes innate lymphoid cells in patients with hepatocellular carcinoma. Gut, 2022, 71, 1161-1175.	6.1	60
5	Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD. Journal of Hepatology, 2022, 77, 748-760.	1.8	57
6	Steatohepatitis Impairs T-cell-Directed Immunotherapies Against Liver Tumors in Mice. Gastroenterology, 2021, 160, 331-345.e6.	0.6	46
7	Activating Mucosal-Associated Invariant T Cells Induces a Broad Antitumor Response. Cancer Immunology Research, 2021, 9, 1024-1034.	1.6	29
8	Videoconference clinics improve efficiency of inflammatory bowel disease care in a remote and rural setting. Journal of Telemedicine and Telecare, 2020, 26, 545-551.	1.4	27
9	Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma. Molecular Therapy - Oncolytics, 2015, 2, 15019.	2.0	21
10	Anti-PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in Mice. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 1166-1178.	2.3	15
11	NAFLD indirectly impairs antigen-specific CD8+ T cell immunity against liver cancer in mice. IScience, 2022, 25, 103847.	1.9	12
12	Assessment of current virotherapeutic application schemes: "hit hard and early" versus "killing softly". Molecular Therapy - Oncolytics, 2015, 2, 15018.	2.0	11
13	Hydroxychloroquine can impair tumor response to anti-PD1 in subcutaneous mouse models. IScience, 2021, 24, 101990.	1.9	11
14	Checkpoint Inhibitors Modulate Plasticity of Innate Lymphoid Cells in Peripheral Blood of Patients With Hepatocellular Carcinoma. Frontiers in Immunology, 0, 13, .	2.2	4
15	Abstract P021: Highly multiplexed spatial analysis of the HCC tumor immune microenvironment using CODEX imaging. Cancer Immunology Research, 2022, 10, P021-P021.	1.6	2
16	Abstract 68: Activating mucosal-associated invariant T cells (MAITs) induces a broad anti-tumor response and offers a novel target for cancer immunotherapy. , 2021, , .		0
17	NAFLD Indirectly Impairs Antigen Specific CD8 T Cell Immunity Against Liver Cancer in Mice. SSRN Electronic Journal, 0, , .	0.4	0
18	693...Mucosal-associated invariant T (MAIT) cell regulation networks in anti-tumor immunity. , 2021, 9, A721-A721.		0

#	ARTICLE	IF	CITATIONS
19	Abstract S02-02: Covid-19 treatment candidate hydroxychloroquine impairs tumor response to anti-PD1. , 2020, , .		0